Antigen Microarrays for the Study of Autoimmune Diseases

Yeste, Ada; Quintana, Francisco J.

doi:10.1373/clinchem.2012.194423

Cited by 27 publications

(26 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since peptides may not be able to capture antibodies that bind to post-translational modifications and conformational epitopes Kodadek and coworkers pioneered the use of libraries of unnatural molecules and specifically peptoids (N-substituted oligoglycine polymers) for the discovery of surrogate antigen biomarkers from patient sera [29,39]. Other powerful methods that are currently used for antigen discovery include antigen microarrays [40,41], nucleic acid programmable protein arrays (NAPPAs) produced using in-vitro transcription/translation[42], peptide arrays [43] or finally arrays based on a different targets such as DNA, peptides and recombinant/native proteins [44]. …”

Section: Antibody Serology: Future Directionsmentioning

confidence: 99%

Serology in the 21st century: the molecular-level analysis of the serum antibody repertoire

Wine

Horton

Ippolito

et al. 2015

Current Opinion in Immunology

View full text Add to dashboard Cite

The ensemble of antibodies found in serum and secretions represents the key adaptive component of B-cell mediated humoral immunity. The antibody repertoire is shaped by the historical record of exposure to exogenous factors such as pathogens and vaccines, as well as by endogenous host-intrinsic factors such as genetics, self-antigens, and age. Thanks to very recent technology advancements it is now becoming possible to identify and quantify the individual antibodies comprising the serological repertoire. In parallel, the advent of high throughput methods for antigen and immunosignature discovery opens up unprecedented opportunities to transform our understanding of numerous key questions in adaptive humoral immunity, including the nature and dynamics of serological memory, the role of polyspecific antibodies in health and disease and how protective responses to infections or vaccine challenge arise. Additionally, these technologies also hold great promise for therapeutic antibody and biomarker discovery in a variety of settings

show abstract

Section: Antibody Serology: Future Directionsmentioning

confidence: 99%

Serology in the 21st century: the molecular-level analysis of the serum antibody repertoire

Wine

Horton

Ippolito

et al. 2015

Current Opinion in Immunology

View full text Add to dashboard Cite

show abstract

“…137 Interestingly, DC vaccination with IL-27-conditioned DCs arrests the immune response directed against the antigen use to induce EAE and also the subsequent spreading of the immune response against additional CNS antigens as measured with antigen arrays. 110,149,150 Taken together, these data demonstrate that IL-27 signaling in DCs limits inflammation in the CNS through CD39-dependent mechanisms. It is still unknown, however, whether this immunoregulatory axis is relevant for the regulation of inflammation in other tissues and whether CD39 is involved in the anti-inflammatory effects of other STAT3-activating cytokines that act on DCs, such as IL-10.…”

Section: Therapeutic Effects Of Vaccination With Il-27 Conditioned Dcsmentioning

confidence: 61%

Role and therapeutic value of dendritic cells in central nervous system autoimmunity

2014

View full text Add to dashboard Cite

Dendritic cells (DCs) are professional antigen-presenting cells that control the generation of adaptive immunity. Consequently, DCs have a central role in the induction of protective immunity to pathogens and also in the pathogenic immune response responsible for the development and progression of autoimmune disorders. Thus the study of the molecular pathways that control DC development and function is likely to result in new strategies for the therapeutic manipulation of the immune response. In this review, we discuss the role and therapeutic value of DCs in autoimmune diseases, with a special focus on multiple sclerosis. Cell Death and Differentiation (2015) 22, 215-224; doi:10.1038/cdd.2014; published online 29 August 2014 FactsDendritic cells (DCs) control central and peripheral tolerance through their effects on effector and regulatory T cells. Specific signaling pathways regulate the ability of different DC populations to promote effector and regulatory T-cell responses. Abnormalities in DC numbers, recruitment and function contribute to the pathology of multiple sclerosis (MS) and can be partially overcome by the use of disease-modifying therapies and the targeting of specific molecular pathways. Nanotechnology provides new tools for the modulation of DC activity in vivo and the therapeutic induction of antigenspecific tolerance in immune-mediated disorders. Open QuestionsAlthough DC populations that promote the development of forkhead box P3-positive (FoxP3 þ ) regulatory T cells (Tregs) have been identified, it is not yet clear whether these populations constitute separate tolerogenic DC lineages or represent alternative activation or maturation states of other DC populations. What are the different molecular pathways that control the DC's ability to prime effector or tolerogenic T-cell responses?There is an unmet clinical need for the development of methods for the efficient and consistent generation of tolerogenic DCs in vitro and in vivo that can be implemented in large-scale clinical setups.Dendritic cells (DCs) are professional antigen-presenting cells (APCs) that control the activation and polarization of T cells into specific lineages and, consequently, the generation of antigen-specific antibody and T-cell responses. 1 In the context of an infectious challenge, the induction of pathogenspecific immune responses provides protective immunity to fight the infection. However, in the context of autoimmune diseases DCs regulate the balance between pathogenic and regulatory immune mechanisms, controlling disease onset and progression. Thus, DCs have a central role in the control of the adaptive immune response to pathogens and selftissues and therefore constitute potential targets for the therapeutic modulation of the immune response. In this review, we discus the role of DCs in autoimmune diseases, with a special emphasis on their role in the modulation of central nervous system (CNS) inflammation in MS. Received 12.6.14; accepted 23.6.14; Edited by H-U Simon; published online 29.8.14 Abbreviations: A...

show abstract

“…Antigen microarrays provide a unique tool to evaluate the immune response in autoimmune disorders, such as the APS [20].…”

Section: Discussionmentioning

confidence: 99%

Diagnostic performance study of an antigen microarray for the detection of antiphospholipid antibodies in human serum

Schindler

Bleher

Thaler

et al. 2015

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

Antigen Microarrays for the Study of Autoimmune Diseases

Cited by 27 publications

References 84 publications

Serology in the 21st century: the molecular-level analysis of the serum antibody repertoire

Serology in the 21st century: the molecular-level analysis of the serum antibody repertoire

Role and therapeutic value of dendritic cells in central nervous system autoimmunity

Diagnostic performance study of an antigen microarray for the detection of antiphospholipid antibodies in human serum

Contact Info

Product

Resources

About